循環器ジャーナル71巻2号

2023年04月発行

特集 今だからこそ聞きたい心不全診療のこと。 Ⅰ．病態

左室逆リモデリングは予見できるか？

著者： 野村征太郎¹

所属機関： ¹東京大学医学部附属病院循環器内科

ページ範囲：P.174 - P.181

POINT
・左室逆リモデリングは遺伝子変異によって予見できる．
・左室逆リモデリングは心筋DNA損傷の定量評価によって予見できる．
・左室逆リモデリングを誘発する治療法が開発されつつある．

参考文献

1）Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling--concepts and clinical implications : a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000 ; 35 : 569-82.

2）Burchfield JS, Xie M, Hill JA. Pathological ventricular remodeling : mechanisms : part 1 of 2. Circulation 2013 ; 128 : 388-400.

3）Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction : pathophysiology and therapy. Circulation 2000 ; 101 : 2981-8.

4）Doughty RN, Whalley GA, Gamble G, et al. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 1997 ; 29 : 1060-6.

5）Januzzi JL Jr, Prescott MF, Butler J, et al ; PROVE-HF Investigators. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA 2019 ; 322 : 1085-95.

6）Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. J Am Coll Cardiol 2019 ; 73 : 1931-44.

7）Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction : a comparative analysis of three randomised controlled trials. Lancet 2020 ; 396 : 121-8.

8）Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy（TRED-HF） : an open-label, pilot, randomised trial. Lancet 2019 ; 393 : 61-73.

9）Burkhoff D, Topkara VK, Sayer G, et al. Reverse Remodeling With Left Ventricular Assist Devices. Circ Res. 2021 ; 128 : 1594-612.

10）Birks EJ, Drakos SG, Patel SR, et al. Prospective Multicenter Study of Myocardial Recovery Using Left Ventricular Assist Devices（RESTAGE-HF［Remission from Stage D Heart Failure］） : Medium-Term and Primary End Point Results. Circulation 2020 ; 142 : 2016-28.

11）McCullough M, Caraballo C, Ravindra NG, et al. Neurohormonal Blockade and Clinical Outcomes in Patients With Heart Failure Supported by Left Ventricular Assist Devices. JAMA Cardiol 2020 ; 5 : 175-82.

12）Aimo A, Gaggin HK, Barison A, et al. Imaging, Biomarker, and Clinical Predictors of Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. JACC Heart Fail 2019 ; 7 : 782-94.

13）日本循環器学会，日本心不全学会．心筋症診療ガイドライン（2018年改訂版）．https://www.j-circ.or.jp/cms/wp-content/uploads/2018/08/JCS2018_tsutsui_kitaoka.pdf

14）Rosenbaum AN, Agre KE, Pereira NL. Genetics of dilated cardiomyopathy : practical implications for heart failure management. Nat Rev Cardiol 2020 ; 17 : 286-97.

15）Tobita T, Nomura S, Fujita T, et al. Genetic basis of cardiomyopathy and the genotypes involved in prognosis and left ventricular reverse remodeling. Sci Rep 2018 ; 8 : 1998.

16）Hasselberg NE, Haland TF, Saberniak J, et al. Lamin A/C cardiomyopathy : young onset, high penetrance, and frequent need for heart transplantation. Eur Heart J 2018 ; 39 : 853-60.

17）Paldino A, Dal Ferro M, Stolfo D, et al. Prognostic Prediction of Genotype vs Phenotype in Genetic Cardiomyopathies. J Am Coll Cardiol 2022 ; 80 : 1981-94.

18）de Frutos F, Ochoa JP, Navarro-Peñalver M, et al ; European Genetic Cardiomyopathies Initiative Investigators. Natural History of MYH7-Related Dilated Cardiomyopathy. J Am Coll Cardiol 2022 ; 80 : 1447-61.

19）Escobar-Lopez L, Ochoa JP, Royuela A, et al. Clinical Risk Score to Predict Pathogenic Genotypes in Patients With Dilated Cardiomyopathy. J Am Coll Cardiol 2022 ; 80 : 1115-26.

20）Nomura S, Satoh M, Fujita T, et al. Cardiomyocyte gene programs encoding morphological and functional signatures in cardiac hypertrophy and failure. Nat Commun 2018 ; 9 : 4435.

21）Ko T, Fujita K, Nomura S, et al. Quantification of DNA Damage in Heart Tissue as a Novel Prediction Tool for Therapeutic Prognosis of Patients With Dilated Cardiomyopathy. JACC Basic Transl Sci 2019 ; 4 : 670-80.

22）Kanamori H, Yoshida A, Naruse G, et al. Impact of Autophagy on Prognosis of Patients With Dilated Cardiomyopathy. J Am Coll Cardiol 2022 ; 79 : 789-801.

23）Morgan BP, Muci A, Lu PP, et al. Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac myosin. ACS Med Chem Lett 2010 ; 1 : 472-7.

24）Malik FI, Hartman JJ, Elias KA, et al. Cardiac myosin activation : a potential therapeutic approach for systolic heart failure. Science 2011 ; 331 : 1439-43.

25）Malik FI, Morgan BP. Cardiac myosin activation part 1 : from concept to clinic. J Mol Cell Cardiol 2011 ; 51 : 454-61.

26）Shen YT, Malik FI, Zhao X, et al. Improvement of cardiac function by a cardiac myosin activator in conscious dogs with systolic heart failure. Circ Heart Fail 2010 ; 3 : 522-7.

27）Bakkehaug JP, Kildal AB, Engstad ET, et al. Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity. Circ Heart Fail 2015 ; 8 : 766-75.

28）Teerlink JR, Diaz R, Felker GM, et al ; GALACTIC-HF Investigators. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. N Engl J Med 2021 ; 384 : 105-16.

29）Lewis GD, Voors AA, Cohen-Solal A, et al. Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction : The METEORIC-HF Randomized Clinical Trial. JAMA 2022 ; 328 : 259-69.

30）Aghajanian H, Kimura T, Rurik JG, et al. Targeting cardiac fibrosis with engineered T cells. Nature 2019 ; 573 : 430-3. Erratum in : Nature 2019 ; 576 : E2.

31）Rurik JG, Tombácz I, Yadegari A, et al. CAR T cells produced in vivo to treat cardiac injury. Science 2022 ; 375 : 91-6.

32）Lu Y, Brommer B, Tian X, et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature 2020 ; 588 : 124-9.

33）Chen Y, Lüttmann FF, Schoger E, et al. Reversible reprogramming of cardiomyocytes to a fetal state drives heart regeneration in mice. Science 2021 ; 373 : 1537-40.

34）Yang JH, Hayano M, Griffin PT, et al. Loss of epigenetic information as a cause of mammalian aging. Cell 2023 ; 186 : 305-326. e27.

35）Lebek S, Chemello F, Caravia XM, et al. Ablation of CaMKIIδ oxidation by CRISPR-Cas9 base editing as a therapy for cardiac disease. Science 2023 ; 379 : 179-85.

36）Yamada S, Ko T, Hatsuse S, et al. Spatiotemporal transcriptome analysis reveals critical roles for mechano-sensing genes at the border zone in remodeling after myocardial infarction. Nat Cardiovasc Res 2022 ; 1 : 1072-83.